



NIH AIDS Reagent Program

20301 Century Boulevard
Building 6, Suite 200
Germantown, MD 20874
USA

Phone: 240 686 4740
Fax: 301 515 4015
aidsreagent.org

DATA SHEET

Reagent: Anti-HIV-1 Nef Monoclonal (EH1)

Catalog Number: 3689

Lot Number: 160244

Release Category: D

Provided: 500 µg of purified antibody at 1.0 mg/mL in PBS, pH 7.4 (sterile filtered and does not contain preservatives)
Endotoxin = 2169.19-21691.97 EU/mg by TAL method
Purity = 98% by SDS-PAGE

Description: A monoclonal antibody to HIV-1 SF2 Nef, specifically the C terminus region (epitope MARELHPEYYKDC)

Host: Balb/c mice

Titer: ELISA: >1:512,000 against cat# 11478, HIV-1 Nef Recombinant Protein.
The user should determine the optimal concentration for any application.

Special Characteristics: This antibody was produced in cell culture and purified by Protein A chromatography. It originates from a hybridoma. The hybridoma was created by immunizing mice with SF2 Nef and fusing the resulting splenocytes with SP2/0 myeloma cells. Please see the [LANL HIV Molecular Database](#) for more information.
EH1 recognizes SF2 and BRU Nef by RIP, Western blot, and IFA.

Recommended Storage: Keep the reagent at 4°C for short term storage and at -80°C for long term storage. Avoid freeze-thaw cycles as reagent degradation may result.

Contributor: Dr. James Hoxie

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

Isotype: IgG₁ κ

References: Chang, A. H., Hoxie, J. A., Cassol, S., O'Shaughnessy, M., & Jirik, F. (1998). Construction of single-chain antibodies that bind an overlapping epitope of HIV-1 Nef. FEBS Lett, 441(2), 307-312. [PUBMED](#)

NOTE: Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Anti-HIV-1 Nef Monoclonal (EH1) from Dr. James Hoxie." Also include the references cited above in any publications.

Last Updated January 22, 2020

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.